Arronax Nantes > Our News
Our News
Production of radionuclides
![Vanessa targeting terbium production 155](/wp-content/uploads/2024/02/Photo_RHODEN-Vanessa-2-290x232.jpg)
Vanessa targeting terbium production 155
29.02.24
Vanessa Rhoden is Brazilian, but she chose to settle in France to do research. A few months into her PhD at the Subatech laboratory, she shares her enthusiasm and the …
![Fatima uses algorithms to track cyclotron anomalies](/wp-content/uploads/2023/11/Fatima-290x232.jpg)
Fatima uses algorithms to track cyclotron anomalies
29.11.23
During her PhD, starting in November 2023, Fatima Basbous, 24, will develop the machine learning algorithms needed to detect anomalies affecting the Arronax cyclotron, so as to optimize the accelerator …
Chemistry and radiopharmacy
![Valery Radchenko at GIP ARRONAX as part of the NExT – ICoN project](/wp-content/uploads/2024/06/20240530_095623_resized-290x232.jpg)
Valery Radchenko at GIP ARRONAX as part of the NExT – ICoN project
03.06.24
From 21 to 31 May, Valery Radchenko, a radiochemist at the TRIUMF particle acceleration centre (Vancouver, Canada), visited GIP ARRONAX in the context of a scientific collaboration to develop new …
![The Nantes astatine project selected by the European Research Council](/wp-content/uploads/2023/02/ERClogo_1-290x232.jpg)
The Nantes astatine project selected by the European Research Council
06.02.23
François Guérard, INSERM UMR 1307 / CNRS UMR 6075, CRCI2NA, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, has been awarded a consolidation grant from the European Research …
Pre-clinical experimentation and clinical research
![ARRONAX and Atonco sign contract to develop an innovative radiopharmaceutical](/wp-content/uploads/2024/04/Atonco-Arronax-2-290x232.jpg)
ARRONAX and Atonco sign contract to develop an innovative radiopharmaceutical
24.04.24
GIP ARRONAX and Atonco (Saint Herblain, France) have joined forces to take the next step in the implementation of alpha-immunotherapy for cancer. Their partnership aims to develop and validate the …
![Oncology: Arronax provides doses for an innovative clinical trial in alpha therapy](/wp-content/uploads/2024/02/GMPS3-2-290x232.jpg)
Oncology: Arronax provides doses for an innovative clinical trial in alpha therapy
06.02.24
Arronax's in-house hospital radiopharmacy is providing all the radiopharmaceutical doses planned for the dose escalation phase of an innovative clinical trial aimed at treating castration-resistant prostate cancer. The aim of …
Non-living and living matter exposed to radiations
![Lunar Radon detectors under test at Arronax](/wp-content/uploads/2022/05/DORN-202205-11-290x232.jpg)
Lunar Radon detectors under test at Arronax
23.05.22
Hosted for 4 days at the GIP ARRONAX, the Toulouse DORN team conducted a measurement campaign to qualify the detectors that will be sent to the Moon in 2024 aboard …
![Nantes at the forefront of research on the FLASH effect](/wp-content/uploads/2022/04/flash.png)
Nantes at the forefront of research on the FLASH effect
07.04.22
Researchers from the ICO (Institut de Cancérologie de l'Ouest), Subatech laboratory and GIP ARRONAX have been collaborating for years to better understand the FLASH effect observed during external irradiation of …
Training activities
![ISI NucMed: end of the 3rd edition!](/wp-content/uploads/2024/07/ISI-NucMed-2024_group_1-290x232.jpg)
ISI NucMed: end of the 3rd edition!
10.07.24
The third edition of the Nantes thematic school dedicated to nuclear medicine was held from 1 to 4 July 2024. Eighteen young researchers, clinicians and students from several countries attended …
![ISI NucMed 2024 : registration is now open!](/wp-content/uploads/2024/02/flyer-ISI-NucMed-2024-1-290x232.jpg)
ISI NucMed 2024 : registration is now open!
06.02.24
The 3rd edition of the ISI NucMed thematic school will be held from 1 to 4 July 2024 in Nantes. Over four days, 20 participants will deepen their knowledge in …